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Caption: Schistosoma mansoni life cycle (1) Paired adult worms (female is thin, male is bigger), (2) Eggs (see note below), 
(3) Ciliated miracidium, (4) Biomphalaria intermediate host snail, (5) Sporocyst, (6) Cercariae, the infective stage, and (7) 
Schistosomula, the young parasite. 
Abstract 
Schistosomiasis is a neglected invasive worm disease with a huge disease burden in developing 
countries, particularly in children, and is seen increasingly in non-endemic regions through transfer by 
travellers, expatriates, and refugees. Undetected and untreated infections may be responsible for the 
persistence of transmission. Rapid and accurate diagnosis is the key to treatment and control. So far, 
parasitological detection methods remain the cornerstone of Schistosoma infection diagnosis in 
endemic regions, but conventional tests have limited sensitivity, in particular in low-grade infection. 
Recent advances contribute to improved detection in clinical and field settings. The recent progress in 
micro- and nanotechnologies opens a road by enabling the design of new miniaturized point-of-care 
devices and analytical platforms, which can be used for the rapid detection of these infections. This 
review starts with an overview of currently available laboratory tests and their performance and then 
discusses emerging rapid and micro/nanotechnologies-based tools. The epidemiological and clinical 
setting of testing is then discussed as an important determinant for the selection of the best analytical 
strategy in patients suspected to suffer from Schistosoma infection. Finally, it discusses the potential 
role of advanced technologies in the setting near to disease eradication is examined. 
Keywords: schistosomiasis, rapid, accurate, POC, diagnosis, immunoassays, PCR, LAMP, 
microfluidic, microarray.  
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Purpose and Rationale:  
The limitations of available diagnostic tests 
for schistosomiasis contribute to our current 
failure in disease control and eradication of this 
important poverty disease. This paper therefore 
aims at delineating specific requirements and 
desirable characteristics for a new generation of 
diagnostics based on the micro- and 
nanotechnologies, driven by the conviction that 
new technologies should benefit all segments of 
humankind, including the poorest. 
Introduction 
Schistosomiasis is one of the most prevalent 
and widespread [1] parasitic neglected tropical 
diseases in the world. It is caused by fluke 
worms of the genus Schistosoma and affects 
humans and various other animals [2, 3]. The 6 
species involved in human infections are S. 
mansoni, S. haematobium, S. japonicum, S. 
mekongi, S. guinensii and S. intercalatum. The 
respective distribution, the population at risk 
and the main clinical manifestations are 
summarized in Table 1.3. Infection starts when 
cercariae released by snails penetrate through 
the skin exposed to infested water [4]. More 
details on the life cycle are given in Figure 1. 
Schistosomiasis affects 221 million people 
where children between 5 and 14 years of age 
which represents 45.8% of the affected patients 
[5] and puts at risk 800 million people in 74 
countries worldwide [6, 7]. In sub-Saharan 
Africa, the number of affected people is 54 
million and 393 million are at risk.[7] 
Worldwide, the disease kills about 300,000 
patients annually [8] and results in 
approximately 25 million disability adjusted 
life years lost [9] despite the implementation of 
control measures [10].  
Selective therapy of school children or mass 
drug administration (MDA) are widely used to 
control schistosomiasis, but fail to prevent rapid 
reinfection in endemic areas [8]. A substantial 
decrease in morbidity and mortality is observed 
in some of these areas, but the disease continues 
to spread to new geographic regions. It is 
increasingly imported into non- or low-endemic 
countries due to the increased migration of the 
human population (e.g., refugees, international 
tourism, and/or international projects) and 
additionally, environmental changes that result 
from development of water resources and 
population growth and migration can facilitate 
the spread of schistosomiasis [11, 12]. 
Diagnostics address both the individual and 
population needs. At the individual level, they 
first can detect disease and identify patients at 
risk of severe disease, which will permit good 
clinical decision making and good case 
management.  
The use of diagnostics also supports (1) the 
detection and prevention of drug resistance, (2) 
the surveillance of a disease, and (3) the 
assessment of the efficacy of drugs and 
vaccines in clinical studies [13]. Rapid and 
accurate diagnosis of schistosomiasis is a 
challenge [14]. It remains a key requirement for 
treatment and control [15-19]. There is still a 
need to determine the existence of infection 
more simply and reliably, both, in hospital 
settings where severe pathological effects are 
suspected, as well as in the field [20, 21].  
The current diagnosis of schistosome 
infection is based mainly on clinical symptoms, 
and therefore low-level and chronic or 
asymptomatic/atypical infections are often 
missed [22, 23]. Various procedures to detect 
this infection have been validated and include 
direct parasitological techniques, immunologic 
methods, and molecular approaches [24]. The 
sensitivity of parasitological tests decreases 
when parasite egg numbers are low or eggs are 
absent [25] and specificity of rapid diagnostic 
tests (RDTs) is variable [24]. Routine 
serological tests such as enzyme-linked 
immunosorbent assay (ELISA) have good 
sensitivity but may cross-react with intestinal 
nematodes [26]. Methods based on the 
amplification of a highly repeated 
deoxyribonucleic acid (DNA) sequence by 
polymerase chain reaction (PCR) in fecal and 
serum human samples [27] show high 
sensitivity, high specificity, and good 
predictive value. Yet, the test cost and the need 
for specific laboratory equipment and 
conditions limit the use of these assays in many 
laboratories. The real-time polymerase chain 
reaction (RT-PCR) method, in spite of its high 
sensitivity and specificity [24], has remained 
only as a confirmatory diagnostic test, since it 
is intensive work and expensive. To reduce the 
costs loop mediated isothermal amplification 
(LAMP) of DNA was developed. Both LAMP 
and microarray methods have been tested and 
so far these methods promise to be excellent 
tools in epidemiological and clinical screenings 
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[1] but, the diagnostic performance of these 
techniques in areas with different 
schistosomiasis prevalence is so variable that it 
is difficult to declare a “gold standard” test [28, 
29]. Also, the amplification mechanism of 
LAMP may easily lead to carryover 
contamination and therefore false-positive 
results.  
The rapid evolution of micro- and 
nanofabrication technologies opens a door for 
the development and evaluation of new 
methods and tools for the diagnosis of 
schistosome infection. In this chapter we will 
first present the currently available diagnostics, 
followed by the latest developments in the field 
and end with a discussion. With a view on 
clinical application, the value of diagnostic tests 
for patients in different epidemiological 
scenarios is discussed. As a comprehensive 
review of the huge body of work that is being 
performed is outside the scope of this paper, we 
aim to provide an update of current relevant 
achievements in the field. The cited articles are 
collected by cross-referencing online keyword 
searches (‘‘Schistosoma diagnostics methods’’ 
‘‘Schistosomisis’’ ‘‘S. mansoni S. 
haematobium S. japonicum’’ ‘‘POC’’) in 
citation and database searching on Pubmed 
from January 1990 to November 2019. The 
works perceived as most important are 
exemplarily presented in this review. The 
emphasis of literature citations is on the 
development of point-of-care diagnostics for 
parasitic infections.  
Established diagnostic assays for 
schistosomiasis 
Current laboratory tests for schistosome 
infection are based on direct parasitological 
detection, the detection of circulating antigens 
and/or specific antibodies, and molecular 
methods. More detailed information can be 
found in focused literature [13, 30]. As the 
background of evaluation for emerging and 
future test modalities, the current clinically 
available tests are summarized in the next 
paragraphs.  
Microscopy: direct detection of parasite eggs 
The reference method for the laboratory 
diagnosis of a schistosome infection is 
parasite egg detection in the infected 
individual’s stool, urine, or tissues [31, 32]. 
Such parasitological detection (PD) is widely 
used because it is relatively efficacious and 
moderately cost-effective for case 
management, screening or surveillance. The 
success of control measures against 
schistosomiasis has been difficult to 
determine because the sensitivity of PD 
decreases when there is no egg excretion, or it 
diminishes, principally in areas of low 
endemicity [25] 
 
   
Figure 1 : Current diagnostics of intestinal schistosomiasis relies on the microscopic detection of S. mansoni eggs in stool 
samples, a laborious, time consuming process relying on infrastructure (microscopes) and  specific expertise. Low-intensity 
infections are frequently missed [Nigo MM, PhD thesis, Basel 2020] 
 
Other direct parasitological tests for intestinal 
schistosomiasis are the Kato-Katz (KK) [33] 
technique, the miracidia hatching test (MHT) 
[34], the salinity gradient [35] and on the 
recently developed FLOTAC [36-41] and 
Helmintex assay [42-47]. The KK technique 
has the advantage of egg quantification in fresh 
stool samples. An amount of approximately 
41.7 mg or 50 mg of feces is placed in a 1.5 mm 
× 6 mm template hole. The number of eggs is 
then counted and extrapolated to 1g [48, 49], 
yielding infection density (Table 2). This 
method is still recommended by the WHO for 
diagnosis at the community level. MHT can be 
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done using the miracidia hatching device [50] 
or by sieving stool sample through a nylon 
tissue bag for concentrating the eggs. Then, 
hatching is carried out in a well-lit room at a 
temperature of 25 ± 3ºC followed by counting 
of the swimming miracidia [34]. The FLOTAC 
technique is more sensitive when compared to 
the KK technique, but it requires specific 
equipment, flotation solution, a suitable 
preservative medium that can affect the 
outcome of the test [41]. The principle of the 
Helmintex test is based on conjugates that are 
formed between the magnetic particles and the 
iron that is present in the eggshell pores of S. 
mansoni. Other factors such as electrostatic 
forces or the surface ornamentation of the eggs 
play also a role [51].  
In urinary schistosome infections, direct 
microscopy of filtered urine is used. After 
gentle homogenization, 10 mL of urine is 
filtered through a membrane on which the 
number of eggs is counted in the microscope at 
40× magnification [52]. These methods are still 
considered as reference methods [53], in spite 
of their limited capability to identify 
schistosome infection consistently in low-
endemic areas. The development of better 
diagnostic tools for case management and 
disease control is therefore required [13]. 
 
 
Table 1: Expression of the intensity of schistosome infection [52] 
Types of 
Schistosomiasis 
Intensity 
expression 
Light Moderate High 
Intestinal 
schistosomiasis 
Eggs per gram 
of stool  
1 – 99  100 – 399  ≥ 400 
Urogenital 
schistosomiasis 
Eggs per 10 mL 
of urine 
< 50 ≥ 50 
 
 
Parasite-derived material detection 
Adequate differentiation between past and 
current infection requires assays, which detect 
circulating parasite antigens. The existence of 
such antigens was first described by [54-65], 
and an inventory has been published [66]. The 
most thoroughly investigated antigens are the 
circulating anodic antigen (CAA) [67], a gut-
associated proteoglycan (GASP) [68] and the 
circulating cathodic antigen (CCA), originally 
named the M-antigen [69], which is a 
polysaccharide antigen emanating from the 
worm gut [70]. They are named relatively to 
their electrophoresis migration [71]. Their 
presence in patients corresponds well with 
active infections [56, 61]. Detection of 
circulating antigens could be used as well as for 
the evaluation of chemotherapy efficacy [6]. 
Other antigens as targets for diagnosis have 
been reported: schistosome adult worm antigen 
(SAWA), schistosome egg antigen (SEA), 
enzymes, parasite proteins, and tegument 
antigens; they can be detected in patient serum 
[72, 73]. As some antigens are cleared by 
kidneys, urinalysis can produce evidence of 
their presence in schistosomiasis due to S. 
japonicum [74], S. haematobium [20] and S. 
mansoni [75]. Antigens from virtually all stages 
of the schistosome life cycle have been tested 
for immunodiagnostic potential and methods 
for their direct detection in blood, stool, or urine 
had been developed. Methods for detecting 
circulating antigens generally involve the 
capture of the antigen by a monoclonal or 
polyclonal antibody, with specificity for 
repeated epitopes on the antigen. In most cases, 
specific monoclonal antibodies are used [74]. 
Examples of these immunoassays are ELISA 
[31], radio-immuno-assay (RIA) [76, 77], and 
direct fluorescent antibody tests [78-80].  
Lateral flow immuno-chromatographic assays 
or RDT are used for diagnosing antigens in 
serum [81], and in urine samples [82, 83]. They 
provide rapid results, are a non-invasive 
technique and are easy to use because they are 
typically cassettes or dipsticks [84, 85]. Details 
on technical procedures can be found in the 
cited literature [86]. Figure 2 shows an RDT for 
CCA in urine for the detection of S.mansoni. 
RDTs permit detection of active infections and 
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are efficient in testing of large numbers of 
samples. However, they are frequently false 
negative due to inhibitory host antibodies [77] 
and often cannot distinguish between infections 
of different species because they are not species 
specific [14]. Diagnostic specificity of these 
tests is high because few false-positive are 
found outside endemic areas and circulating 
antigen levels generally correlate with excreted 
egg counts [87-89]. AgD assays need to be 
evaluated further and are not currently 
considered as a suitable replacement for 
traditional diagnostic tests [28, 29]. 
 
Figure 2: Rapid diagnostic test for circulating cathodic 
antigen allows point-of-care diagnosis of Schistosoma 
infection. Field studies [Nigo MM, PhD thesis, Basel 
2020] have shown very good sensitivity when prevalence 
and parasite load is high, but sub-optimal sensitivity for 
low-grade infection. 
Antibody detection (AbD) 
Schistosoma infection activates specific 
immunoglobulin-dependent responses against 
several parasite antigens [90]. Most AbD assays 
measure serum immune reactivity to SAWA 
and SEA preparations for diagnostic purposes, 
using crude extracts, or parasite tegument 
proteins. AbD assays exhibit a modest 
sensitivity and a limited specificity although 
several antigens are available for diagnostic 
purposes, and some studies have shown their 
superiority to parasitological methods in low-
endemic areas (LEAs) [91]. Nonetheless, AbD 
is more attractive for monitoring areas of 
controlled transmission and are important for 
the diagnosis of atypical forms like schistosome 
neuro-infection [22, 23]. Screening and 
diagnosis should rely on the use of 2 or more 
immunological tests to improve sensitivity 
because the test result depends on worm 
burden. 
AbD assays include various forms of RIA and 
ELISA, indirect immunofluorescence (IIF), 
complement fixation, indirect agglutination of 
erythrocytes or other tests, of which each has 
their specific weaknesses [92]. Many of these 
diagnostic techniques were miniaturized. 
Detection of antibodies in patient serum or 
cerebrospinal fluid (CSF) became possible 
[93]. Most AbD assays exhibit high sensitivity; 
however, they show limited specificity due to 
crude antigen preparations. They allow early 
diagnosis before oviposition of the worm [94, 
95]. With the interpretation of the results, one 
has to take into account a possible persistence 
of host antibodies after the patient is cured [96, 
97]. 
Alternative methods 
Hematuria and proteinuria are associated with 
S. haematobium infection and are therefore 
often used for indirect diagnosis or as screening 
tool for schistosome infection [97, 98]. The 
cheap urine dipsticks for macroscopic 
hematuria and proteinuria detection are being 
used to guide treatment and public health 
interventions for S. haematobium. Hematuria is 
relatively specific for infection in a S. 
haematobium endemic area. However, 
hematuria has a variable sensitivity [99].  
Molecular approaches 
Although PD methods have proven to be 
inadequate as a gold standard, advances in the 
development of antigen and antibody detection 
assays are not sufficient to allow their use either 
universally or as a reliable single detection 
approach in schistosomiasis diagnosis, 
particularly in areas of low endemicity [24]. To 
overcome the shortcomings of both 
parasitological and immunological methods, 
the development of more sensitive and more 
specific molecular diagnostic tools diagnosis is 
desirable. The availability of DNA detection 
techniques may evolve to potentially valuable 
tools in the diagnosis of a schistosome 
infection. DNA-based assays have also proven 
to be useful for cure assessment [24]. The PCR 
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technique has shown its clinical value in a wide 
variety of infectious diseases and in a variety of 
sample types including blood, urine, and saliva 
[100]. It has been successfully used for the sex 
determination of the cercariae in Schistosoma 
sp. studies and in the development and 
application of new techniques to generate 
expressed sequence tags. Hamburger et al. 
[101, 102] developed a PCR protocol that was 
based on the amplification of a highly repetitive 
DNA sequence for monitoring S. mansoni 
infestation in water-based on DNA sequences 
from S. mansoni cercariae. According to 
Reithinger et al. [103], PCR assays can be 
divided into 3 distinct formats: namely the mid-
tech approach, represented by conventional 
PCR, the high-tech represented by real-time 
PCR and the low-tech, represented by LAMP. 
PCR-based methods are considered to be highly 
sensitive and a detection limit is 1 fg of S. 
mansoni of genomic DNA has been reported 
[24]. PCR can be performed on feces, urine or 
serum [27, 73, 104]. In other studies, the use of 
PCR has been reported for diagnosing female 
genital S. haematobium infection and low 
intensity of S. japonicum infections in stool 
samples [105, 106], and for detection and 
quantification of S. mansoni and S. 
haematobium when present with other parasitic 
co-infections [107]. Superior accuracy, 
sensitivity, and specificity in areas with a low 
intensity of infection have been observed using 
antigen detection by PCR-based methods. It can 
be used to efficiently detect an active infection 
in almost 60% of IgG positive individuals who 
do not excrete eggs [104, 108]. Different 
studies demonstrated that the absence of 
amplification of other helminth DNA in a PCR 
assay is a strong indicator of its species-
specificity [109]. Thus, PCR is more sensitive 
than the KK technique. However, Gomes and 
Enk [104, 110] found different results in 
samples tested by conventional PCR and 
microscopy. They observed that up to 41.6% of 
samples negative by KK are positive by PCR 
and that PCR assays for S. mansoni diagnosis 
increase prevalence estimates to above 38%, 
whereas positivity on K-K assay ranges from 18 
to 30.9%. A high degree of specificity may 
render it preferable to serological techniques. 
Even though these studies have demonstrated 
that PCR-based technologies are reliable, 
specific and sensitive tools, they are not widely 
used in low-income countries because highly 
skilled personnel and expensive cyclers are 
needed. The use of thermocycler machines to 
amplify DNA is severely hampered in field 
situations where electric power is unstable, 
intermittent or absent. There is a real need to 
render these techniques easier to use and 
technically more robust, such that obvious 
advantages of these tests can be translated into 
broad clinical utility even in resource-
constrained locations [111, 112].  
The value of standardized quantitative PCR-
based methods for the detection of Schistosoma 
infection was shown in experimental settings 
[94]. RT-PCR was found highly sensitive and 
specific in the detection of active 
schistosomiasis [109]. Wichmann [113] found 
that blood-based RT-PCR detected 95% of true 
positive patients when, in contrast, anti-
schistosome antibodies and microscopy were 
positive only in 72% and 25% of cases 
respectively. Moreover, RT-PCR also permits 
the determination of infection intensity in 
samples with a low parasite burden. Obeng 
[114] examined urine specimens from children 
to detect CCA, and then performed RT-PCR on 
urine sample after storage at −80ºC using 
internal-transcribed-spacer-2 (ITS2) sequences 
for S. haematobium. When compared with eggs 
in the urine, the RT-PCR test was 100% 
sensitive, yet specificity was low. The 
detectable product was dependent on the 
number of eggs passed in the specimen and the 
authors postulated that the template DNA was 
derived from the eggs. 
Currently, all PCR variants demand more 
sophisticated laboratory equipment and a 
greater operational effort when compared with 
the KK technique, in terms of low costs and 
ease of operation [27]. 
New DNA detection using new technologies, 
such as LAMP (Figure 3), have been 
developed. LAMP amplifies a few copies of 
DNA to 10⁹ copies in less than an hour with 
high specificity and efficiency under isothermal 
conditions. LAMP method employs a Bacillus 
stearothermophilus (Bst) DNA polymerase and 
a set of 4 [115] to 6 or more specially designed 
primers: inner forward primer (FIP), inner 
backward primer (BIP), outer forward primer 
(F3), outer backward primer (B3), loop forward 
(LF) and loop backward that recognize a total 
of 6 distinct sequences on target DNA. A 
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standard LAMP reaction consists of a large 
number of reaction components, namely the 
enzyme and its buffer, 3 sets of primers of 
varying concentrations, and a detection dye. 
Significant progress has been made with the 
modification of the LAMP method. The LAMP 
reaction produces large amounts of magnesium 
pyrophosphate (Mg₂P₂O₇) and double-stranded 
(dsDNA) avoiding post DNA amplification 
manipulation. LAMP has shown high 
sensitivity, detecting 0.08 fg of genomic DNA 
[116].
 
 
Figure 3: Isothermal loop-mediated amplification (LAMP) for the detection of Schistosoma DNA. Yellow colour indicates 
detection of specific DNA. A1-6: Schistosoma positive snails; A7-8: negative controls. B: evaluation of LAMP result with 
agarose electrophoresis: B1-5,8: negative control. B6-7: Schistosoma positive snails. The reduced hardware requirements for 
LAMP compared to conventional PCR and the simple, colorimetric readout may lead to field-applicable high-sensitivity 
molecular testing. From Hamburger et al [118]. 
 
 
The LAMP method has the advantage of 
being able to amplify target DNA from partially 
processed and/or non-processed samples [117]. 
It can be conducted in less advanced field 
laboratories with much less intensive training 
of local laboratory personnel. When a large 
number of examinations are undertaken, the use 
of LAMP method could save time and financial 
resources [118]. This method has demonstrated 
superior accuracy when compared to the 
conventional PCR in detecting several 
pathogens such as viruses, bacteria, protozoa in 
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humans [119]. In the diagnosis of 
schistosomiasis, LAMP was found highly 
sensitive for the detection of S. japonicum 
infection pre- and post-chemotherapy in 
experimental settings [120]. LAMP was 
recently used for the detection of S. japonicum 
in human serum samples. It revealed high 
analytical sensitivity (96.7%) detecting 0.08 fg 
of parasite DNA and a specificity of 100% 
[121]. Fernandez-Soto [1] are leading in 
development of a sensitive, specific, cost-
effective and easy to perform LAMP assay for 
early diagnosis of S. mansoni in feces. 
However, the amplification mechanism of 
LAMP may easily lead to carryover and 
therefore false-positive results.  
Emerging diagnostic technologies for 
schistosomiasis 
Advances in micro-and nanofabrication 
technologies have greatly contributed to 
improving POC laboratory diagnosis [122]. 
Benefits of miniaturization include low 
consumption of costly reagents and power, 
minimized handling of hazardous materials, 
short reaction times, portability and versatility 
in design, and capability for parallel operation, 
all of which are particularly important for POC 
diagnosis in the tropical and developing 
countries where schistosomiasis is endemic 
[123]. Important developments in this field are 
presented below in Table 2.  
Table 2: Comparison of the main characteristics of diagnostic tests for schistosome infection 
Characteristics 
Test Methods Advantages Disadvantages Price 
(US$) 
On 
market 
 
Reference 
Microscopy Egg 
detection 
Simple 
Quantification 
Limited 
sensitivity 
Laborious 
0.4 Yes 
 
[77] 
ELISA; 
DDIA; IHA 
Antibody 
Detection 
Sensitive Limited 
specificity 
5.0*
* 
Yes [52] [124] 
RDTs Antigen 
Detection 
Rapid; Large 
scale testing; 
Specific  
Variable 
sensitivity; False 
positives 
2.6 Not 
yet 
[77] [78] 
ELISA 
DDIA*** 
IHA**** 
Antigen 
Detection 
Sensitive 
Specific  
Variability in 
test results 
 Yes [126] 
[127] [128] 
PCR DNA 
detection 
Highly 
sensitive 
Specific 
Laborious; 
Expensive; 
Instrumentation; 
Not quantitative 
6.4 Yes [17] [106] 
RT-PCR RNA 
detection 
Highly 
sensitive 
Quantitative 
Laborious; 
Expensive; 
Instrumentation; 
7.7 Not 
yet 
[114] 
[128] 
LAMP DNA 
detection 
Highly 
sensitive 
Accurate  
Some 
Instrumentation, 
false positive 
 Not 
yet 
[1] [75] 
[120] [129] 
* Price without including equipment use and personnel labor [24] 
 ** Estimated price 
DDIA = disperse dye immunoassay; DNA = deoxyribonucleic acid; ELISA = enzyme-linked immunosorbent 
assay; IHA = indirect hemagglutination test; LAMP = loop mediated isothermal amplification; RNA = ribonucleic 
acid. 
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Song et al. [129] presented an instrument-free 
disposable microfluidic POC device for the on-site 
detection of schistosome parasite infection in blood 
samples obtained from a finger prick. On board a 
reaction chamber is present and once filled with 
water, it is heated to its operating temperature, which 
is used to incubate a LAMP reaction. The emission 
of fluorescent light is detected by eye or with the 
camera of a smartphone. 
 
 
Figure 4: A compact disc (CD)-like microfluidic rotating disc for DNA hybridization assays in nanoliter samples proposed 
by Li et al [128, reprinted with permission]. Fluid handling is driven by differential rotation of the disk, allowing flow control 
without the need to interact with the disk. Parallel processing can be performed on multiple channels.  
This device has potential, however, the 
discussed crossover contamination when using 
LAMP needs to be taken into account and thus 
a second test confirming an infection might be 
necessary.  
A microfiltration device for the diagnosis of 
urogenital schistosomiasis was developed by 
Xiao Y et al. [130], shown in Figure 5
 
 
Figure 5: Microfluidic device for trapping and fluorescence-based identification of Schistosoma hematobium eggs from 
urine. A: microfluidic trap. B: trapped Schistosoma eggs in brightfield imagine. C: with fluorescence microscopy overlay. 
Adapted from Xiao Y et al [130, reprinted with permission]. 
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In this device S. haematobium eggs are 
trapped and analysed by using brightfield 
microscopy. For POC use, it might be possible 
to design this device such that a smartphone 
camera can be used. 
Capillary test strips or LF assays can also be 
considered as fairly simple microfluidic 
systems and are the most successful POC tests 
to date. LF devices can be reduced to their bare 
ingredients - patterned filter paper impregnated 
with reagents resulting in microfluidic paper-
based analytical devices (μPADs). Paper-based 
techniques allow performing multiple, 
simultaneous, and independent assays with 
multiplexed detection. Fast prototyping and 
production techniques for paper-based 
diagnostic devices have been proposed [123]. 
μPADs are inexpensive, easy to use, 
lightweight to transport, compatible with 
biological samples and may be handled in 
remote settings by non-trained personnel.  
Ishii [131] developed microfluidic 
quantitative PCR (qPCR) on environmental 
samples in a quadruplicate with a dynamic 
array under specific detection conditions. They 
found that the quantitative performance of 
microfluidic qPCR was similar to the 
conventional qPCR. However, it specifically 
detected pathogens in stool, demonstrating that 
this method may be applied to the rapid 
identification of disease causing-agents for 
diagnostic purposes. They also quantified 
multiple targets simultaneously in water 
samples. Therefore, they concluded that the 
microfluidic qPCR systems can be applied to 
the quantification of multiple pathogens in 
environmental samples. Despite the efforts 
made in developing microfluidic POC 
diagnostic devices, microfluidic systems for 
detection of schistosome infection are 
developed but still in its infancy due to issues 
as device sensitivity, multiplex analysis 
capabilities, assay stability/shelf life, and 
fabrication cost remain. Standardized 
evaluation of the performance microfluidic 
versus other POC technologies in a real-world 
setting is needed. 
Microarrays 
Microarrays are usually a glass slide but may 
also be a microtitre plate or on board of a 
microfluidic device. Small areas or micro-wells 
are coated with different probes or biological 
material for the simultaneous detection of 
multiple targets. In this way, thousands of 
biomolecular interactions can be probed in 
parallel [132]. Microarrays can offer multi-
component information, dynamic 
compensation for sample matrix effects, 
detection of malfunction/deterioration, and 
improved selectivity through signal pattern 
analysis. Recent progress has brought 
microarrays to the forefront of clinical 
diagnostics and medical research. DNA 
microarrays appear suited for highly parallel 
detection and identification of microorganisms 
from clinical samples [133] and therefore 
promise more rapid, accurate, and cost-
effective detection of pathogens compared to 
culture techniques or conventional 
immunoassays.  
Genomes of all 3 major schistosome species 
have been sequenced [134], and several 
postgenomic approaches and high throughput 
methods have been developed to take 
advantage of this wealth of information [135]. 
One such approach is a schistosome-specific 
microarrayed protein, containing 232 unique 
antigens [136]. Many of these arrayed proteins 
are novel molecules and the majority is from S. 
japonicum, with the remainder from S. 
mansoni. They can be then probed with 
antibodies from immune hosts as a powerful 
new technology for vaccine antigen discovery 
[137]. Using this approach, McWilliam [138] 
identified several novel antigens, which may be 
important targets for vaccine development. 
Nanotechnology enabled diagnostics 
Nanotechnology is based on structures and 
materials in the nanometre size range. Such 
nano-sized structures and materials differ from 
microscale structures and materials in various 
aspects, for example in the very high surface 
per weight, the occurrence of specific physical 
effects like particle surface plasmon effects not 
readily observed in the micro- or macro scale. 
Gold nanoparticles are stable, can bind 
biomolecules, and are already used widely in 
many different kinds of applications such as 
imaging and biomedical diagnosis [139]. An 
example is the amperometric immunosensor for 
the detection of S. japonicum antigen [140]. 
This sensor is made of carbon paste coated with 
a layer of chitosan on which a monolayer of 
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gold nanoparticles was formed. Antibodies 
against S. japonicum antigen were linked to the 
gold monolayer and used to detect this antigen 
with a detection limit of 0.06 μg/mL [141]. 
More recent work is the highly sensitive 
detection of S. mansoni DNA [142], where 
aminated magnetic particles and gold 
nanoparticles are immobilized on monolayers 
of mercaptobenzoic acid. Thiolated DNA 
probes are immobilized on the surface of the 
nanoparticles. Evaluation of the surface was 
performed by using an atomic force microscope 
and the electrochemical processes (binding of 
the antigens) were measured by using 
electrochemical impedance spectroscopy and 
cyclic voltammetry. S. mansoni DNA from 
cerebrospinal fluid and serum could be detected 
with a detection limit of 0.685 and 0.781 pg/μL 
respectively. Such sensors will require further 
development to render their application suitably 
simple and robust for application in the field 
[143].  
Diagnostic tests in the “real world” of 
field practice 
Parasitological methods 
In most locations worldwide and in particular, 
in endemic areas, laboratory diagnosis of 
schistosomiasis is still based on parasite egg 
detection in feces or urine. Direct or indirect 
microscopy remains in use in POC although 
being laborious, and of limited sensitivity 
because of the daily egg count fluctuation. 
However, negative microscopy does not 
disprove the possibility of infection in people 
living in or coming from endemic areas. Results 
need to be validated by improved diagnostic 
techniques. Urine microscopy after 
centrifugation or filtration is required for 
urogenital schistosomiasis [144]. It presents a 
good specificity but a low sensitivity 
consecutive to variable egg release. 
Nevertheless, in endemic settings, efficiency 
could reach when urine is collected between 10 
am and 2 pm according to the egg excretion 
pattern [73]. However, during field surveys, 
urine microscopy presents some difficulties. 
Immunoassays 
Immune host response against schistosome 
antigens has been an alternative way for 
diagnosis. For many years several 
immunodiagnostic techniques have been 
developed. AbD immunoassays are widely 
used. However, since CCA and CAA can be 
detected by substituting other antigens, both 
processes can indiscriminately be used. 
Immunoassays based on CAA, SAWA or SEA 
circulating antibodies detection are already in 
use. Their validity is usually variable. 
Immunoassays complete direct microscopy by 
detection of specific antibodies in serum and 
cerebrospinal fluid. AbD is the best tool for 
field diagnostic activities. However, they 
usually exhibit a weak specificity. Frequently, 
reaction with other parasites antigens 
compromises the specificity. Nevertheless, 
antigens used in immunoassays have proven 
crucial test sensitivity and specificity element 
[145]. 
Molecular methods 
Molecular methods present high performance 
in use [104, 111]. PCR is highly accurate, 
highly sensitive and specific for the detection of 
S. mansoni. They also permitted S. mansoni 
increased prevalence estimates, whereas KK 
assay underestimated them. However, [107] 
reported discordant results in samples tested by 
conventional PCR and KK techniques, and 
negative PCR results in KK-positive samples. 
RT-PCR was found highly specific and 
sensitive in S. japonicum and S. haematobium 
detection [114]. Compared to microscopy and 
immunoassays, RT-PCR can be the best marker 
after chemotherapy [104]. Although owning 
these qualities, PCR and RT-PCR are 
cumbersome and costly methods. Nucleic acid 
extraction stages improvement could perhaps 
lead to cost reduction [104]. DNA detection 
development by LAMP technologies promises 
to be the best alternative [116, 120].  
Emerging technologies 
The persistent transmission and widespread 
distribution of schistosome infection call for the 
development of new “gold standard” diagnostic 
assays. Identification and detection of infected 
hosts as well as new diagnostic tests for field 
applications [118] are essential for case 
management and disease control. These tests 
must be more sensitive, more specific, and 
affordable for point-of-care diagnostic 
strategies (see also Table 3.3). There are 2 
important challenges: (1) although 
parasitological tests remain central for 
schistosomiasis diagnosis, they have proven 
their accuracy inability, (2) immunoassays and 
usual molecular techniques have demonstrated 
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their weaknesses. To overcome these 
shortcomings, resorting to statistical indirect 
methods to assess the accuracy is frequently 
required. For example, the use of latent class 
analysis (LCA) [21, 84, 146] has proven its 
capability for validation of the sensitivity and 
specificity of the tests [21].  
 With the goal of the development of an 
automated and/or integrated device, 
microfluidic platforms procure hope. 
Miniaturization could enable affordable POC 
diagnostic tests for end-users in low resource 
settings [147, 148] 
 
Table 3: Criteria/wish list for future diagnostic tests [116, 148, 149] 
ASSURED criteria:  
Affordable by those at risk of infection (less expensive for patients and for health services); 
Sensitive (few false negatives): able to diagnose light infections (1 egg per gram for intestinal and 1 
egg/10 mL for urinary schistosomiasis); 
Specific (few false-positives); 
User-friendly (simple to perform in a few steps with minimal training); 
Robust (Field-adapted: stable in ambient temperature conditions - from 4 to 30ºC) - does not 
require refrigerated storage) and rapid (results available in 30 minutes); 
Equipment free (less instrumentation, no computer use); 
Deliverable to the end users 
Inexpensive to produce (cost target of less than 1 US$ per test to ensure commercial viability) 
Producing a visual readout (results can be read by naked eyes) 
Using non-invasive samples (urine, stool, saliva, sputum) 
New challenges and uncertainties for 
more adapted tests in different 
settings 
Clinical scenarios for schistosomiasis test 
vary widely: For disease control in 
communities with a very high prevalence, a test 
with imperfect sensitivity will predictably be 
associated with a significant number of false 
negatives, rendering treatment of everybody the 
most rational approach and implying that 
individual testing only adds cost without adding 
benefit and is therefore not required. In 
contrast, in a low-prevalence situation near the 
eradication threshold, where infection severity 
typically is also low, a test with low sensitivity 
may miss many of those with persistent, but low 
parasite load, so that the infection cycle is not 
interrupted and completing eradication 
becomes infeasible. In this situation, a test with 
near perfect sensitivity like LAMP would be 
needed to identify affected individuals, but 
because most individuals undergoing the test 
will be negative, such testing may become 
unaffordable for developing countries. The 
situation is yet different in travellers from 
affluent countries, where optimal sensitivity is 
desired, and event relatively costly tests are 
economically feasible. 
Despite the impressive advances on the 
technology front, an integrated approach with 
practical, adapted, affordable rapid diagnostic 
tools in combination with suited clinical and 
epidemiologic testing strategies is still to be 
defined. Recent clinical observations of lower 
than expected current cure rates with the 
mainstay of therapy, praziquantel, particularly 
when sensitive testing is used for treatment 
success monitoring, also raise the concern of 
slow, but progressive drug resistance 
development. This would add to the challenge 
for novel tests that not only detect a parasite 
but also determine its sensitivity to standard 
drug treatment.  
Reliable access to electricity for diagnostic 
devices, even simple microscopes, is a 
pervasive problem in developing countries.  
Fortunately, recent progress in miniaturization, 
battery technology, low power embedded high 
performance computing[149] and solar cell 
technology has led to development of portable, 
battery driven diagnostic devices for parasitic 
disease, e.g. portable microscopy [150] and 
portable molecular diagnostics like LAMP 
[151] that are suited for use in very low 
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resource environments. Thus, alternative 
energies have the capability to benefit 
developing countries and basic healthcare 
profoundly. 
Table 4: Needs of schistosomiasis tests according to different settings 
Schistosoma infection diagnostic 
methods 
Needs 
Parasitological Improved microscopy 
Immunoassays RDTs; Dipsticks 
Molecular Miniaturized LAMP 
Emerging Microfluidic point-of-care devices (mobile phone based) 
LAMP = loop mediated isothermal amplification; RDT = rapid diagnostic test. 
Conclusion 
Current parasitological methods have well-documented weaknesses. They are often too resource-
consuming, laborious or expensive for broad use in endemic areas. In addition, they often do not allow 
distinction between latent versus recent infection. Immunoassays that have long been perceived as 
replacement or second option because of their high sensitivity, often fail due to their low specificity. 
However, combination of several test modality may improve reliability of testing, but this involves 
increased cost and time consumption. Use of molecular techniques offers a real alternative because they 
offset the weaknesses of the other methods while enhancing their strengths. Nevertheless, they remain 
laborious and expensive. The LAMP approach to nucleic acid detection appears to be a valuable 
platform but needs further development in terms of miniaturization, reduction of carryover 
contamination risk and develop instrumentation that is field-ready. New microfluidic devices have a 
significant potential for improving diagnosis based on protein and nucleic acid detection. The 
integration of multiple test modalities into a robust point-of-care device that is easy to handle and fulfills 
the ASSURED criteria appears technically feasible and when applied to the diagnosis of Schistosoma 
may revolutionize clinical diagnosis and greatly enhance public health efforts in this important disease.  
Thus, there remains a significant unmet need for new tests that are highly sensitive, highly specific, 
adapted to field conditions and allow point-of-care diagnosis, are inexpensive and are suited to 
contribute either to mass treatment in high prevalence areas, eradication in low-prevalence areas, or 
individual diagnosis in symptomatic individuals outside such scenarios. The rapid evolution observed 
in nanotechnologies and microfluidics, as well as in molecular diagnostics, will hopefully render 
technologic progress also beneficial for the poorest in regions where testing may contribute most to 
humankind. 
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